Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of captopril to inhibition of scar hyperplasia

A scar hyperplasia and scar technology, which is applied in the direction of medical preparations containing active ingredients, organic active ingredients, skin diseases, etc., can solve the problems of few and few, and achieve the effect of small dosage, mature technology and small side effects

Inactive Publication Date: 2012-02-01
PLASTIC SURGERY HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are very few relevant studies and reports on the prevention and treatment of captopril for pathological scars as a fibrotic disease of the skin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of captopril to inhibition of scar hyperplasia
  • Application of captopril to inhibition of scar hyperplasia
  • Application of captopril to inhibition of scar hyperplasia

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0018] Preparation of Captopril Cream:

[0019] Substrate: 4-10% by weight of stearic acid, 1-2% of Span, 4-10% of stearyl alcohol, 6-12% of liquid paraffin, 4-10% of white vaseline to prepare solution A; Tween 3-10% %, glycerin 4-20%, sorbic acid 0.2%, distilled water 50-70% to prepare solution B. Heat liquids A and B to 80°C respectively, slowly add liquid B into liquid A, stir until nearly coagulated, and obtain a matrix for later use.

[0020] 80-88% of distilled water is dissolved in 6-20% of captopril according to the weight ratio; an equal amount of matrix is ​​added to the solution, and 3-10% of captopril cream is obtained by condensation.

experiment example 1

[0023] Experimental Example 1: Clinical application of pathological scar patients

[0024] 30 patients with pathological scars were selected from plastic surgery hospitals. The specimens were specimens of pathological scars that needed plastic surgery 5-8 months after burns, including 12 males and 18 females; aged 17-39 years; Earlobe, chest, and legs respectively. Method of use: 5% captopril cream externally applied to the scar area, 3 times / day, 5-100mg / cm each time 2 . Blood pressure was monitored at 0.5 hour, 1 hour, and 2 hours after use; scar treatment was evaluated after 3 months of use, which were good effect, improved, ineffective, and severe. After the patient used it for 3-7 months, no skin allergic reaction and other adverse reactions occurred, and no obvious fluctuations in blood pressure were monitored. Gross observation and histological observation showed that the scars treated with captopril were dark red in color, raised on the surface, and soft in texture;...

experiment example 2

[0025] Experimental Example 2: Preventive application for postoperative patients

[0026] Select 30 patients undergoing surgery in a plastic surgery hospital, and apply preventively to the wound site. Among them, there were 15 males and 15 females, aged 6-33 years. Method of use 5% captopril cream is externally applied to surgical wound site, 3 times / day, 5-100mg / cm each time 2 . Blood pressure was monitored at 0.5 hour, 1 hour, and 2 hours after use; scar treatment was evaluated after 3-6 months of use, which were severe hyperplasia, moderate hyperplasia, and no hyperplasia. After the patient used it for 3-7 months, no skin allergic reaction and other adverse reactions occurred, and no obvious fluctuations in blood pressure were monitored. No scar hyperplasia occurred in 29 cases, and moderate hyperplasia occurred in 1 patient, whose symptoms improved after 3 months of continuous use. The effect of preventing hyperplasia is very obvious.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of captopril to the preparation of medicaments for treating and / or inhibiting scar hyperplastic diseases. Particularly, the hyperplastic diseases comprise hyperplastic scar, cheloid, urethral scar stricture and silicon gel breast augmentation prosthesis postoperative capsular contracture. When the diseases are treated, the captopril is used as an active ingredient, clinically-used emulsifiable paste, gel, injection and the like in different formulations are prepared by the conventional preparation process. The study indicates that the captopril can reduce the capacity of synthesizing pathologic scar fibroblast collagen and secreting the collagen, weaken the multiplication capacity of fibroblasts and reduce the expression of transforming growth factor-beta 1 (TGF-beta 1), and has a good treatment or prevention effect on pathologic scars. Simultaneously, the captopril acts on scar tissue directly, has the advantages of small dose, high curative effect, small side effect, mature raw material process, readily available materials, low cost and the like, and is expected to become a main medicament for treating and preventing the scars clinically.

Description

technical field [0001] The present invention relates to a new application of captopril, specifically a new application of captopril in the preparation of therapeutic or preventive drugs for inhibiting scar hyperplasia. Background technique [0002] Captopril, also known as captopril, is 1-(3-mercapto-2-D-methylpropionyl)-L-proline, the structure is: [0003] [0004] It is white or off-white crystalline powder, has a special smell similar to garlic, tastes salty, slightly soluble in water, easily soluble in ethanol. Captopril is the earliest angiotensin-converting enzyme inhibitor used clinically. With the in-depth research on the renin-angiotensin system, it is realized that angiotensin not only exists in the blood circulation, but also exists in various Various tissues, such as blood vessels, kidneys, adrenal glands, brain, pituitary gland, and uterus, play a variety of physiological roles. Since it came out in the 1990s, Captopril has developed from a special drug fo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/401A61P17/02A61P17/04
Inventor 潘博蒋海越郄淑燕严笠刘学红庄洪兴
Owner PLASTIC SURGERY HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com